OSE Immunotherapeutics gets first patient dosed in RENGEVITY-201
OSE Immunotherapeutics said its licensee Veloxis Pharmaceuticals announced the first patient has been dosed in RENGEVITY-201, a Phase 2 trial evaluating pegrizeprument (VEL-101) for kidney transplant rejection prevention.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.